That, says PhRMA, the industry’s lobby based in Washington, DC, is because price regulations seen in other rich countries “chill innovation, impede patients’ access to the newest cutting-edge medicines, and trigger innovators to relocate to countries with more progressive public policy.
基于1个网页-相关网页
应用推荐